Avicanna Inc. (AVCNF)
- Previous Close
0.2332 - Open
0.2638 - Bid --
- Ask --
- Day's Range
0.2332 - 0.2332 - 52 Week Range
0.1780 - 0.5320 - Volume
65 - Avg. Volume
8,581 - Market Cap (intraday)
22.833M - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
www.avicanna.com87
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AVCNF
Performance Overview: AVCNF
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVCNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVCNF
Valuation Measures
Market Cap
22.83M
Enterprise Value
23.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.62
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.07%
Return on Assets (ttm)
-26.46%
Return on Equity (ttm)
-152.97%
Revenue (ttm)
16.79M
Net Income Avi to Common (ttm)
-8.74M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
477.2k
Total Debt/Equity (mrq)
22.62%
Levered Free Cash Flow (ttm)
-3.91M
Research Analysis: AVCNF
Company Insights: AVCNF
AVCNF does not have Company Insights